Oversight Without Control: A guide for Virtual Pharma Manufacturers
/ Sponsor-Side Batch Intelligence

Oversight Without Control: A guide for Virtual Pharma Manufacturers

Oversight Without Control: A guide for Virtual Pharma Manufacturers
  • Ensure continuous adherence to ALCOA+ principles and 21 CFR Part 11 requirements.
  • Achieve auditable oversight of manufacturing data without altering CDMO workflows.
  • Prevent the compounding financial costs of delayed product release and scrapped batches.

Gain control over your manufacturing data

Download the white paper

By submitting your details, you agree to our Privacy Policy , and to receive email communications from Mareana. You may unsubscribe at any time.

Customers who trust us

Key Takeaways

With Mareana, you can achieve genuine, auditable oversight of CDMO manufacturing data and operationalize exception-based review, without requiring your manufacturing partners to alter a single shop-floor workflow.

In this whitepaper, you will learn

  • How specialized document extraction models effectively process unstructured, non-standard CDMO formats.

  • Why traditional digital solutions like EDMS and web portals fail to resolve the CDMO data bottleneck.

  • A comprehensive evaluation framework for selecting a sponsor-side batch intelligence platform.

  • The importance of contextualization in automatically mapping extracted data to specific batches and materials.

Good Manufacturing
Practice

Connected Data Deep Insights.

Good Manufacturing
Practice

Connected Data Deep Insights.

/ ANY QUESTIONS? WE'D LOVE TO HELP

Frequently Asked Questions

The “oversight without control” problem refers to the situation where virtual pharmaceutical companies are fully responsible for product quality and regulatory compliance, yet rely on CDMOs for manufacturing data they do not control. This creates a gap where sponsors must make critical release decisions based on delayed, unstructured, and externally generated data.

Paper-based batch records introduce delays, lack standardization, and are often converted into non-searchable PDFs. This creates a “hybrid system” that regulators identify as high-risk for data integrity issues, especially under increasing scrutiny from agencies like the FDA.

Regulatory bodies, particularly the FDA, are shifting toward continuous, data-driven compliance monitoring. The surge in warning letters—many tied to data integrity and vendor oversight—signals that reliance on outdated documentation systems is no longer acceptable.

A sponsor-side intelligence model is a system that operates independently of CDMO infrastructure. It ingests data in any format (paper, PDF, or electronic), extracts and contextualizes it using AI, and enables efficient review through automation and exception-based workflows. Mareana’s Manufacturing Intelligence platform is an example of software that help pharma manufacturers to achieve sponsor-side intelligence.

Key criteria include:

  • CDMO-agnostic data ingestion

  • Regulatory validation readiness

  • Contextual data structuring (e.g., knowledge graphs)

  • Exception-based workflows

  • Continuous learning capabilities

8 AI use cases to transform your quality assurance.
/ BEFORE YOU GO

8 AI use cases to transform your quality assurance.

By signing up, you agree to the Privacy Policy.